Efficacy of topical application of a proprietary compound Z in a humanized mouse model of psoriasis

Completed

• Conditions: flaking disease; psoriasis; 10003816; 10014982

• Registration Number: NL-OMON32781
• Lead Sponsor: TNO

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 26

Inclusion Criteria

Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use local corticosteriods or ointments to prevent dry skin (see appendix 2).

Exclusion Criteria

These patients have not received light therapy or another form of systemic treatment (methotrexaat, cyclosporin A, anti-TNF treatments). Gender or age of the adults are not a exclusion criteria.(see appendix 2)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Efficacy of the therapy is tested by histology and immuno-histochemical<br /><br>techniques in the transplanted biopsies.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Furthermore, the presence of compound Z will be evaluated in the skin after<br /><br>treatment.</p><br>